Description

Viroltif® is a prescription systemic antiviral medicine containing the active substance valganciclovir. It is used for the treatment and prevention of cytomegalovirus (CMV) infection, especially in patients with weakened immune systems, including transplant recipients.

The drug works by suppressing viral DNA replication, which prevents the virus from multiplying and spreading within the body.

🔹 Pharmacological Group

Systemic antiviral agents,
subgroup — antiherpetic medicines.

ATC code: J05AB14

🔹 Active Substance

Valganciclovir — 450 mg (per tablet)

🔹 Mechanism of Action

After absorption, valganciclovir is rapidly converted into its active metabolite — ganciclovir, which:

• selectively inhibits viral DNA polymerase;

• blocks viral DNA replication;

• suppresses cytomegalovirus (CMV) multiplication;

• reduces viral load in the body.

This helps control viral activity and prevent complications.

🔹 Indications for Use

The medicine is used:

🟢 In adults

• treatment of CMV retinitis in patients with AIDS;

• prevention of CMV infection in patients after kidney, heart, or liver transplantation.

🟢 In children

• prevention and treatment of CMV infection in children with immunodeficiency conditions (as prescribed by a physician).

🔹 Method of Administration

• Tablets are taken orally, without chewing, with water.

• Dosage is determined individually by a doctor depending on age, body weight, kidney function, and clinical condition.

• Dose adjustment is required in patients with renal impairment.

• Treatment must be conducted under medical supervision.

🔹 Contraindications

• hypersensitivity to valganciclovir or any component of the product;

• severe renal impairment without appropriate dose adjustment;

• pregnancy and breastfeeding (unless otherwise prescribed by a physician).

🔹 Warnings and Precautions

✔️ Renal function monitoring (creatinine, clearance) is required during treatment.
✔️ Regular monitoring of white blood cell counts is necessary to detect myelosuppression.
✔️ Bone marrow suppression may occur, therefore frequent laboratory monitoring is needed.
✔️ Immunocompromised patients should receive treatment under supervision of an infectious disease specialist or oncologist.

🔹 Adverse Reactions

May include (not a complete list):

Most common:

• nausea, vomiting, diarrhea;

• headache, dizziness;

• fatigue;

• leukopenia, thrombocytopenia.

Less common:

• anemia;

• increased creatinine levels;

• sleep disturbances;

• skin rash.

If severe symptoms occur, consult a doctor immediately.

🔹 Drug Interactions

Valganciclovir may interact with other medications and affect renal clearance. Patients should inform their doctor about all medicines they are taking, including supplements.

🔹 Storage Conditions

• store at temperatures not exceeding 25°C;

• protect from light and moisture;

• keep out of reach of children;

• do not use after the expiry date.

🔹 Special Instructions

✔️ Dispensed only with a prescription.
✔️ Do not change the dose or discontinue treatment without consulting a doctor.
✔️ If a dose is missed, take it as soon as possible, but do not double the next dose.